socalTECH

JULY 2, 2014

San Diego-based Ocean Aero , a developer of unmanned, autonomous marine vehicles, has scored funding from Thousand Oaks-based Teledyne , the companies said this morning. Financial terms of the investment were not disclosed. According to Teledyne, the investment also included a strategic partnership deal.

Thousand Oaks 147

Thousand Oaks Invest San Diego Design 147

socalTECH

JANUARY 22, 2010

invested in Southern California in Q4. was invested in Southern California, as well as Q4 of last year, when $508.2M was invested in the region. However, nationally, venture capital numbers were much worse, with venture investments dropping to the lowest level in more than a decade. in investments. in investments.

Southern California 154

Southern California Venture Capital Invest Orange County 154

socalTECH

JULY 6, 2015

Thousand Oaks-based Teledyne Technologies has increased its stake in San Diego-based Ocean Aero , a developer of unmanned, robotic underwater and surface vehicles used for the scientific, defense, and oil and gas market, the company said late Friday. Teledyne made its initial investment in Ocean Aero in July of 2014.

Thousand Oaks 100

Thousand Oaks San Diego Invest Marketing 100

socalTECH

JANUARY 22, 2010

invested in Southern California in Q4. was invested in Southern California, as well as Q4 of last year, when $508.2M was invested in the region. However, nationally, venture capital numbers were much worse, with venture investments dropping to the lowest level in more than a decade. in investments. in investments.

Southern California 113

Southern California Invest Venture Capital Orange County 113

Xconomy

JULY 22, 2016

It’s the first partnership for Jounce, and a big one: the startup got a $225 million up front cash payment from Celgene and a $36 million equity investment. —Bruce Bigelow profiled Dauntless Pharmaceuticals , a stealthy biotech company creator in San Diego forming single-drug startups.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

—Gene therapy news: After investing in Bamboo Therapeutics and its Duchenne muscular dystrophy treatment earlier this year, Pfizer bought the Chapel Hill, NC-based biotech outright on Monday for $150 million up front , with potentially another $495 million later. . Regeneron is paying $25 million upfront.

News 40

News Thousand Oaks Pricing Report 40

Xconomy

AUGUST 26, 2016

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. A Phase 2 trial of the drug, AMX0035, should start in late 2016 or early 2017.

Pricing 40

Pricing Thousand Oaks Startup Research 40